Specialised Therapeutics Expands Opzelura Partnership in Australia
Singapore, September 21, 2026 Specialised Therapeutics (ST) has expanded its existing partnership with Incyte to include ruxolitinib cream (Opzelura®)...
Vitiligo
Advertisement
Accro Bioscience Gains NMPA Clearance for AC-201 Vitiligo Trial
New York and Suzhou, China, September 8, 2026 Accro Bioscience has announced a major clinical development milestone for AC-201,...
Teva Reports Positive Phase 2a Results for TEV ‘408 in Celiac Disease
TEL AVIV, Israel, September 2, 2026 Teva Pharmaceutical Industries Ltd. has reported positive topline results from its ongoing Phase...
argenx Completes Forte Biosciences Acquisition for FB102
Amsterdam, the Netherlands – August 27, 2026 argenx announced the successful completion of its acquisition of Forte Biosciences, Inc.,...
Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo
NEW YORK, July 30, 2026 Pfizer Inc. announced positive topline Phase 3 results for LITFULO™ (ritlecitinib) in patients with...
Advertisements
AbbVie Gains EU Approval for RINVOQ in Vitiligo Care
North Chicago, Ill., July 29, 2026 AbbVie announced that the European Commission (EC) has approved RINVOQ® (upadacitinib) for the...
InnoCare Reports Positive Phase II Soficitinib Results
Beijing, July 16, 2026 InnoCare Pharma announced that the Phase II portion of its adaptive Phase II/III clinical trial...
Clinuvel Advances Vitiligo Phase 3 with EMA Support
MELBOURNE, Australia & AMSTERDAM, Netherlands, April 24, 2026 Clinuvel Pharmaceuticals Ltd has announced that it has received final Scientific...
Advertisement
